Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Total Current Assets
All assets expected to be converted to cash or used up within one year.
Zura Bio LimitedNASDAQ: ZURA
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 32.2% from a year ago
Total current assets stood at $227M at the end of Q1 FY2026, up 32.2% from a year earlier and up 102.1% from the prior quarter. Over 3 fiscal years it compounded at +298.4% a year.
Context
- Total current assets amounted to 99.3% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +32.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 112.31M USD
- Year-over-year change
- -37.2%
- 4-year CAGR
- +214.2%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 112.31M | -37.2% |
| FY2024 | 2024-12-31 | 178.74M | +77.2% |
| FY2023 | 2023-12-31 | 100.84M | +5578.1% |
| FY2022 | 2022-12-31 | 1.78M | +54.2% |
| FY2021 | 2022-03-31 | 1.15M | — |
Total Current Assets vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 total current assets of $227M is the 3rd highest of the 11 companies compared; the peer median is $143.06M.
- Its year-over-year change of +32.2% is the 3rd highest of 11, against a peer median of -24.2%.
- Total current assets amounts to 99.3% of total assets for ZURA, versus a peer median of 79.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $161.41B | +422369.0% | +17.5% | 75.1% | |
| Mar 2026 | $232.61M | +143.5% | +37.9% | 98.8% | |
ZURAZura Bio Limited | Mar 2026 | $227M | +32.2% | +298.4% | 99.3% |
| Mar 2026 | $216.88M | -22.2% | -15.7% | 88.4% | |
| Mar 2026 | $188.06M | -16.6% | -22.6% | 84.6% | |
| Mar 2026 | $178.41M | -26.5% | -13.1% | 56.7% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $107.72M | -26.3% | +52.5% | 100.0% |
| Mar 2026 | $98.83M | -30.2% | -17.3% | 55.6% | |
| Mar 2026 | $96.56M | +2.2% | -18.3% | 71.5% | |
| Mar 2026 | $93.58M | -39.5% | +89.3% | 94.9% | |
| Mar 2026 | $45.57M | -59.3% | -27.2% | 70.9% | |
| Peer median (excluding ZURA) | $143.06M | -24.2% | -14.4% | 79.9% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.